Focused On-demand Library for Multivesicular body subunit 12B

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9H7P6

UPID:

MB12B_HUMAN

Alternative names:

ESCRT-I complex subunit MVB12B; Protein FAM125B

Alternative UPACC:

Q9H7P6; Q8N6S7

Background:

Multivesicular body subunit 12B, also known as ESCRT-I complex subunit MVB12B or Protein FAM125B, plays a crucial role in the ESCRT-I complex. This complex is pivotal for the vesicular trafficking process, specifically required for sorting endocytic ubiquitinated cargos into multivesicular bodies. The precise mechanisms and interactions of MVB12B within cellular processes highlight its significance in maintaining cellular homeostasis.

Therapeutic significance:

Understanding the role of Multivesicular body subunit 12B could open doors to potential therapeutic strategies. Its involvement in the regulation of vesicular trafficking and endocytic cargo sorting positions it as a key player in cellular function and health. Exploring its functions further could unveil novel approaches to targeting diseases related to vesicular transport dysfunctions.